4/8
02:28 am
dsnky
ATLATL Announces Agreement with Daiichi Sankyo to Deepen APAC Biotech Innovation [Yahoo! Finance]
Low
Report
ATLATL Announces Agreement with Daiichi Sankyo to Deepen APAC Biotech Innovation [Yahoo! Finance]
4/1
03:34 pm
dsnky
Can Tempus AI's (TEM) ALERT Trial Quietly Redefine Its Real-World Data Advantage in Cardiology? [Yahoo! Finance]
Low
Report
Can Tempus AI's (TEM) ALERT Trial Quietly Redefine Its Real-World Data Advantage in Cardiology? [Yahoo! Finance]
4/1
09:03 am
dsnky
Nuvation Bio gains global rights to brain cancer therapy from Daiichi Sankyo [Seeking Alpha]
Low
Report
Nuvation Bio gains global rights to brain cancer therapy from Daiichi Sankyo [Seeking Alpha]
3/31
09:27 pm
dsnky
Tempus AI Daiichi Sankyo Tie Up Highlights Precision Oncology Opportunity [Yahoo! Finance]
Medium
Report
Tempus AI Daiichi Sankyo Tie Up Highlights Precision Oncology Opportunity [Yahoo! Finance]
3/28
03:12 am
dsnky
Daiichi Sankyo's ADC Alliances Test Valuation Gap In Oncology Strategy [Yahoo! Finance]
Low
Report
Daiichi Sankyo's ADC Alliances Test Valuation Gap In Oncology Strategy [Yahoo! Finance]
3/25
08:30 am
dsnky
Tempus Announces Strategic Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Clinical Differentiation Across an ADC Clinical Program
Low
Report
Tempus Announces Strategic Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Clinical Differentiation Across an ADC Clinical Program
3/18
11:21 am
dsnky
Is Now The Right Time To Reassess Daiichi Sankyo (TSE:4568) After Recent Share Price Weakness? [Yahoo! Finance]
Low
Report
Is Now The Right Time To Reassess Daiichi Sankyo (TSE:4568) After Recent Share Price Weakness? [Yahoo! Finance]
3/18
08:30 am
dsnky
Leveragen Announces Collaboration with Daiichi Sankyo to Support Development of Advanced Biologics Using Next-Gen In Vivo Antibody Discovery Platforms [Yahoo! Finance]
Low
Report
Leveragen Announces Collaboration with Daiichi Sankyo to Support Development of Advanced Biologics Using Next-Gen In Vivo Antibody Discovery Platforms [Yahoo! Finance]
3/17
09:05 am
dsnky
Voro Therapeutics Announces Research Collaboration with Daiichi Sankyo to Advance PrimeBody™ Technology for Next-Generation Tumor-Activated ADCs [Yahoo! Finance]
Medium
Report
Voro Therapeutics Announces Research Collaboration with Daiichi Sankyo to Advance PrimeBody™ Technology for Next-Generation Tumor-Activated ADCs [Yahoo! Finance]
3/16
02:32 pm
dsnky
Guggenheim Lifts PT on AstraZeneca PLC (AZN) to 16,000 GBp From 15,500 GBp [Yahoo! Finance]
Low
Report
Guggenheim Lifts PT on AstraZeneca PLC (AZN) to 16,000 GBp From 15,500 GBp [Yahoo! Finance]
3/12
04:14 am
dsnky
Allegro's osteoarthritis hydrogel resolves lameness in animal study [Yahoo! Finance]
Low
Report
Allegro's osteoarthritis hydrogel resolves lameness in animal study [Yahoo! Finance]
3/9
10:36 pm
dsnky
AstraZeneca Oncology Updates Prompt Fresh Look At Valuation And Growth Potential [Yahoo! Finance]
Low
Report
AstraZeneca Oncology Updates Prompt Fresh Look At Valuation And Growth Potential [Yahoo! Finance]
3/9
07:16 am
dsnky
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer [Yahoo! Finance]
Low
Report
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer [Yahoo! Finance]
3/9
02:46 am
dsnky
ENHERTU® Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer [Yahoo! Finance]
Low
Report
ENHERTU® Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer [Yahoo! Finance]
3/9
02:30 am
dsnky
ENHERTU® Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer
Low
Report
ENHERTU® Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer
3/5
07:52 am
dsnky
Daiichi and GAIA join forces to commercialise digital cardiovascular therapy [Yahoo! Finance]
Low
Report
Daiichi and GAIA join forces to commercialise digital cardiovascular therapy [Yahoo! Finance]
3/5
02:15 am
dsnky
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe. [Yahoo! Finance]
Low
Report
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe. [Yahoo! Finance]
3/5
02:00 am
dsnky
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.
Low
Report
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.
3/4
03:10 pm
dsnky
ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M [Yahoo! Finance]
Low
Report
ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M [Yahoo! Finance]
3/4
06:16 am
dsnky
Esperion to acquire Corstasis for cardiovascular franchise expansion [Yahoo! Finance]
Low
Report
Esperion to acquire Corstasis for cardiovascular franchise expansion [Yahoo! Finance]
3/3
10:05 am
dsnky
Antibody-drug Conjugates (ADCs) in Oncology Market Competitive Landscape Report 2026: Comprehensive Insights About 200+ Companies and 220+ Drugs by Product Type, Stage, and Route of Administration [Yahoo! Finance]
Low
Report
Antibody-drug Conjugates (ADCs) in Oncology Market Competitive Landscape Report 2026: Comprehensive Insights About 200+ Companies and 220+ Drugs by Product Type, Stage, and Route of Administration [Yahoo! Finance]
3/3
08:23 am
dsnky
CellCarta Appoints Ehab A. El-Gabry, MD, as Chief Medical Officer & Head of Companion Diagnostics to Advance CDx Strategy, Digital Pathology and AI [Yahoo! Finance]
Medium
Report
CellCarta Appoints Ehab A. El-Gabry, MD, as Chief Medical Officer & Head of Companion Diagnostics to Advance CDx Strategy, Digital Pathology and AI [Yahoo! Finance]
2/27
07:38 am
dsnky
What Daiichi Sankyo Company (TSE:4568)'s ENHERTU EMA Filing and AI Oncology Push Mean For Shareholders [Yahoo! Finance]
Low
Report
What Daiichi Sankyo Company (TSE:4568)'s ENHERTU EMA Filing and AI Oncology Push Mean For Shareholders [Yahoo! Finance]
2/19
07:00 pm
dsnky
Daiichi Sankyo Appoints John Tsai, MD as Global Head of R&D
Low
Report
Daiichi Sankyo Appoints John Tsai, MD as Global Head of R&D
2/19
02:30 am
dsnky
ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer
Low
Report
ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer